Showing 3331-3340 of 4063 results for "".
- Sight Sciences Appoints Ali Bauerlein as Chief Financial Officerhttps://modernod.com/news/sight-sciences-appoints-ali-bauerlein-as-chief-financial-officer/2481509/Sight Sciences announced the appointment of Alison “Ali” Bauerlein as its Chief Financial Officer and Treasurer, effective April 3, 2023. “I am incredibly excited to have Ali join Sight Sciences as we scale our business and drive toward profitable growth
- Aviceda Announces 3 Presentations on AVD-104, its Lead Glyco-mimetic Nanoparticle, As Treatment for GA at ARVOhttps://modernod.com/news/aviceda-announces-3-presentations-on-avd-104-its-lead-glyco-mimetic-nanoparticle-as-treatment-for-ga-at-arvo/2481507/Aviceda Therapeutics announced its upcoming oral and poster presentations at the 2023 Association for Research in Vision and Ophthalmology (ARVO) annual meeting in New Orleans, April 23-27, 2023. Detailed results from each of these three studies will be reported at the conference.
- Nicox Announces Presentations of Additional NCX 470 Data at the Upcoming World Glaucoma Congresshttps://modernod.com/news/nicox-announces-presentations-of-additional-ncx-470-data-at-the-upcoming-world-glaucoma-congress/2481481/Nicox SA announced presentations of additional NCX 470 data at the 10th World Glaucoma Congress (WGC), which will be held from June 28 to July 1, 2023 in Rome, Italy. Details of the presentations: Poster Title: Effects of NCX 470, a Nitric Oxide (NO)-Donati
- Graybug Announces Name and Trading Symbol Changehttps://modernod.com/news/graybug-announces-name-and-trading-symbol-change/2481478/Graybug Vision announced that it has changed its name to CalciMedica Inc., effective today. In connection with the name change, the company has changed its trading symbol to “CALC.” The company’s common stock will commence trading on March 21, 2023 on the Nasdaq Global
- CooperVision Launches Major US Myopia Control Advocacy and Education Campaignhttps://modernod.com/news/coopervision-launches-major-us-myopia-control-advocacy-and-education-campaign/2481474/CooperVision has unveiled a multifaceted consumer and professional marketing campaign to protect children’s vision and advance myopia control education in the United States to kick off Vision Expo East 2023. The “Make Children’s Sight Your Fight” initiative is rooted in ne
- BioCareSD and AllyRetina GPO Partner to Help Retina Providers Improve Patient Care and Increase Efficiencyhttps://modernod.com/news/biocaresd-and-allyretina-gpo-partnership-to-help-retina-providers-improve-patient-care-and-increase-efficiency/2481473/BioCareSD announced its partnership with AllyRetina. Debuting at the American Society of Retina Specialists (ASRS) 24th Annual Business of Retina conference this week, AllyRetina will serve its GPO members through its physician leadership, a seasoned management team, and innovative tools and
- CXL Ophthalmics Appoints Tiffany Haynes as Vice President of Clinical Operationshttps://modernod.com/news/cxl-ophthalmics-appoints-tiffany-haynes-as-vice-president-of-clinical-operations/2481468/CXL Ophthalmics announced that Tiffany Haynes has been appointed as Vice President of Clinical Operations. With more than 25 years of experience in ophthalmology, Ms. Haynes previously served as Global Director, Medical Affairs for Johnson & Johnson Vision. There, she was respo
- Harrow Announces Transitional Pass-Through Reimbursement Status for IHEEZOhttps://modernod.com/news/harrow-announces-transitional-pass-through-reimbursement-status-for-iheezo/2481462/Harrow announced that the Centers for Medicare & Medicaid Services (CMS) has approved transitional pass-through reimbursement status for IHEEZO (chloroprocaine hydrochloride ophthalmic gel, 3%), which is indicated for ocular surface anesthesia. Beginning April 1, 2023, and
- Ophtec Celebrates 40 Year Anniversary with New Brand Identityhttps://modernod.com/news/ophtec-celebrates-40-year-anniversary-with-new-brand-identity/2481460/Ophtec is celebrating its 40th anniversary in 2023 and launching a new brand identity, "Modernized and fit for the future." Ophtec was founded in 1983 by the Dutch ophthalmologist Prof. Dr. Jan Worst, also known as the inventor of the world’s first Iris fi
- Study: Iyuzeh Demonstrated Similar IOP Lowering Efficacy with a Favorable Safety Profile when Compared to Xalatanhttps://modernod.com/news/study-iyuzeh-demonstrated-similar-iop-lowering-efficacy-with-a-favorable-safety-profile-when-compared-to-xalatan-in-glaucoma-patients/2481450/Thea Pharma announced the presentation of phase 3 data on Iyuzeh (latanoprost ophthalmic solution 0.005%) by Jason Bacharach, MD, at the 2023 American Glaucoma Society (AGS) Annual Meeting. The large, pivotal clinical trial demonstrated comparable efficacy of preservative-free